Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.
The company’s pipeline targets urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning, supported by a strong global supply, manufacturing, and distribution network.
Telix has received regulatory approvals from the FDA, TGA, and Health Canada for its prostate cancer imaging agent and has over 18 clinical trials underway worldwide.
